Cardiol Therapeutics Inc(CRDL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRDL Cardiol Therapeutics Inc

Not Yet Opened 11-21 16:00:00 EST

1.58

+0.02

+1.28%

盘后1.58

+0.000.00%

17:17 EST

High1.60	Low1.49	Vol678.59K
Open1.59	D1 Closing1.56	Amplitude6.73%
Mkt Cap126.24M	Tradable Cap120.09M	Total Shares79.90M
T/O1.03M	T/O Rate0.89%	Tradable Shares76.01M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CRDL","market":"US","secType":"STK","nameCN":"Cardiol Therapeutics Inc","latestPrice":1.58,"timestamp":1732222800000,"preClose":1.56,"halted":0,"volume":678592,"hourTrading":{"tag":"盘后","latestPrice":1.58,"preClose":1.58,"latestTime":"17:17 EST","volume":345,"amount":547.3528,"timestamp":1732227472159},"delay":0,"floatShares":76009100,"shares":79900089,"eps":-0.394772,"marketStatus":"Not Yet Opened","change":0.02,"latestTime":"11-21 16:00:00 EST","open":1.59,"high":1.595,"low":1.49,"amount":1034566.8413312,"amplitude":0.067308,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.394772,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732266000000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":1.56,"preHourTrading":{"tag":"盘前","latestPrice":1.6098,"preClose":1.56,"latestTime":"09:11 EST","volume":24,"amount":38.6388,"timestamp":1732198311446},"postHourTrading":{"tag":"盘后","latestPrice":1.58,"preClose":1.58,"latestTime":"17:17 EST","volume":345,"amount":547.3528,"timestamp":1732227472159},"volumeRatio":1.059879,"impliedVol":0.19,"impliedVolPercentile":0.0079},"requestUrl":"/m/hq/s/CRDL","defaultTab":"news","newsList":[{"id":"2484608025","title":"Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484608025","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484608025?lang=en_us&edition=fundamental","pubTime":"2024-11-19 00:37","pubTimestamp":1731947820,"startTime":"0","endTime":"0","summary":"Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week study. MAvERIC-Pilot results support advancing CardiolRx into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 clinical trials. The MAvERIC-Pilot study enrolled 27 participants  at eight clinical sites across the United States. Average disease duration and the number of pericarditis episodes per year prior to trial entry were 2.7 years and 5.8 events per year, respectively. Baseline pericarditis pain score averaged 5.8 out of 10 and the C-reactive protei","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SNLatFs9t095hO6ZfF5o6Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/5649ee63ca7bc5515f8119ab3d294731","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SNLatFs9t095hO6ZfF5o6Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/5649ee63ca7bc5515f8119ab3d294731"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cardiol-therapeutics-phase-ii-maveric-163700007.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-phase-ii-maveric-163700007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","AFG","BK4117","LENZ","BK4007","CRDL","BK4107"],"gpt_icon":1},{"id":"2483085371","title":"Cardiol Therapeutics Inc reports results for the quarter  - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483085371","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483085371?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:03","pubTimestamp":1731679396,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics Inc reports results for the quarter  - Earnings SummaryCardiol Therapeutics Inc CRDL.TO reported a quarterly adjusted loss of 18 cents per share for the quarter , lower than the s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nL8N3MM15S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDL"],"gpt_icon":0},{"id":"2483789002","title":"Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2483789002","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483789002?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:00","pubTimestamp":1731502800,"startTime":"0","endTime":"0","summary":"Company advancing late-stage clinical programs with novel therapies that target underserved heart diseases. NEW YORK, Nov. 13, 2024  -- PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc.  has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector. Cardiol’s focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate CardiolRx, positions it as a pioneer in addressing major unmet needs in cardiac care.Recurrent pericarditis affects approximately 38,000 patients in the United States annually who have experienced at least one recurrence. The global pericarditis market was valued at $2.44 billion in 2023 and is projected to grow at a CAGR of 5.24% during the forecast period of 2024-2032, reaching $3.87 billion by 2032.In addition, Cardiol is advancing CRD-38, a proprietary subcutaneously","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4mLU.0ORbBAziimH5lwK5w--~B/aD0xNTAwO3c9MTUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/371a8f2aeb61f9794e5eaec23621376a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4mLU.0ORbBAziimH5lwK5w--~B/aD0xNTAwO3c9MTUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/371a8f2aeb61f9794e5eaec23621376a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-inc-added-prism-130000195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRDL","BK4007"],"gpt_icon":1},{"id":"2482420129","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2482420129","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482420129?lang=en_us&edition=fundamental","pubTime":"2024-11-11 19:00","pubTimestamp":1731322800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Angi Inc Class A                                3Q       .00       AMC. ·Global Ship Lease                                3Q      2.41   8:00 AM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI","IAC","AMTX","CRVO","KEP","DDI","GAUZ","IKT","ATER","NRGV","CNNE","ICL","ARMK","ASRT","FLNG","CLRB","RVPH","LAZR","GATO","XGN","OBIO","CNTA","EARN","ABSI","DAVE","XP","AZN","DHX","GENI","SGMT","INTS","EQ","MLYS","NOTE","FIHL","TWKS","CRDL","DHT","DAVA","TSVT","CHGG","CCLD","ABOS","BLFS","CYTH","FBRX","AXSM","FTCI","AVTE","CAE"],"gpt_icon":0},{"id":"2482745272","title":"Cardiol Therapeutics Inc  expected to post a loss of 11 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482745272","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482745272?lang=en_us&edition=fundamental","pubTime":"2024-11-09 06:20","pubTimestamp":1731104421,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics Inc  expected to post a loss of11cents a share - Earnings Preview Cardiol Therapeutics Inc CRDL.TO  is expected to show no change in quarterly revenue when it reports  results on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL8N3MF41J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRDL"],"gpt_icon":0},{"id":"2477135974","title":"Are Medical Stocks Lagging  Cardiol Therapeutics (CRDL) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2477135974","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477135974?lang=en_us&edition=fundamental","pubTime":"2024-10-22 21:40","pubTimestamp":1729604413,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Cardiol Therapeutics Inc.  one of those stocks right now?A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Cardiol Therapeutics Inc. is a member of the Medical sector. This group includes 1025 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Cardiol Therapeutics Inc. is currently sporting a Zacks Rank of #2 .Another Medical","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/132juehTNIyEUn7pK7.GPA--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/132juehTNIyEUn7pK7.GPA--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-cardiol-therapeutics-134013393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CTLT","CRDL","BK4585","BK4530","BK4588"],"gpt_icon":0},{"id":"2477438145","title":"Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis","url":"https://stock-news.laohu8.com/highlight/detail?id=2477438145","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477438145?lang=en_us&edition=fundamental","pubTime":"2024-10-22 18:30","pubTimestamp":1729593000,"startTime":"0","endTime":"0","summary":"MAVERIC-2 trial will evaluate the impact of CardiolRx following cessation of interleukin-1 blocker therapy  and is expected to run concurrently with the Company's planned Phase III program.IL-1 is a key pro-inflammatory cytokine in the pathophysiology of recurrent pericarditis. It is generated downstream following activation of the NLRP3 inflammasome and amplifies the autoinflammatory response characteristic of the disease. IL-1 blockers  target and negate the activity of IL-1, but given their expense and immunosuppressant risks, they are generally prescribed as a third-line intervention in difficult-to-treat patients. There is a growing body of evidence indicating pericarditis recurrence rates are as high as seventy-five percent and onset is rapid following cessation of IL-1 blocker thera","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lX.QzNqzG.VIVWVm.XSEnQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/d68c2d33547d61f2e98b3e3432e19738","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lX.QzNqzG.VIVWVm.XSEnQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/d68c2d33547d61f2e98b3e3432e19738"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cardiol-therapeutics-advance-cardiolrx-tm-103000954.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-advance-cardiolrx-tm-103000954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4588","WRD","BK4099","TM","BK4139","BK4555","LENZ","CRDL","BK4585","03160","SSI"],"gpt_icon":0},{"id":"2474874099","title":"Cardiol Therapeutics Closes $13.5 Million Public Offering; Shares Rise 2% Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2474874099","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474874099?lang=en_us&edition=fundamental","pubTime":"2024-10-11 21:07","pubTimestamp":1728652028,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics  said in a regulatory filing Thursday that it has closed its public offering of 8,437,500 class A common shares at $1.60 per share for gross proceeds of $13.5 million.The life sciences company said it plans to use the net proceeds to support the clinical development of CardiolRx to treat recurrent pericarditis, as well as for general and administrative expenses, working capital, and other expenses.Shares of Cardiol Therapeutics were up 2.2% in recent premarket activity.Price: 1.8191, Change: +0.04, Percent Change: +2.20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","LENZ","CRDL"],"gpt_icon":0},{"id":"2474745813","title":"Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2474745813","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474745813?lang=en_us&edition=fundamental","pubTime":"2024-10-10 21:09","pubTimestamp":1728565740,"startTime":"0","endTime":"0","summary":"Oakville, Ontario-- - Cardiol Therapeutics Inc.   , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, confirmed today that it has successfully closed its previously announced public offering  of 8,437,500 Class A common shares of the Company  at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million, before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering.As previously stated, the Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.Canaccord Genuity acted as the sole bookrunner in connection with the Offering.Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b1gcR4DNZCtSn7RSomBmYg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/caab765f61bf56882817554fede74765","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b1gcR4DNZCtSn7RSomBmYg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/caab765f61bf56882817554fede74765"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cardiol-therapeutics-announces-closing-us-130900455.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-announces-closing-us-130900455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRDL","BK4007","BK4139","LENZ"],"gpt_icon":0},{"id":"2474728564","title":"Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2474728564","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474728564?lang=en_us&edition=fundamental","pubTime":"2024-10-09 04:01","pubTimestamp":1728417660,"startTime":"0","endTime":"0","summary":"The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis, and for general and administrative expenses, working capital and other expenses.Canaccord Genuity is acting as the sole bookrunner in connection with the Offering.The Offering is expected to be priced in the context of the market, with the final terms of the Offering to be determined at the time of pricing. There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. The closing of the Offering will be subject to customary closing conditions, including the listing of the Common Shares on the Toronto Stock Exchange  and the Nasdaq Capital Market  and any required approvals of the TSX and Nasdaq.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/unSoJ_lB7HG306sI7Btxsw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/caf2fd47a619de46b2266065cd6db22a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/unSoJ_lB7HG306sI7Btxsw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/caf2fd47a619de46b2266065cd6db22a"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cardiol-therapeutics-files-preliminary-prospectus-200100894.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-files-preliminary-prospectus-200100894.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4007","CRDL","LENZ"],"gpt_icon":0},{"id":"2469646217","title":"Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis","url":"https://stock-news.laohu8.com/highlight/detail?id=2469646217","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469646217?lang=en_us&edition=fundamental","pubTime":"2024-09-24 19:27","pubTimestamp":1727177220,"startTime":"0","endTime":"0","summary":"Toronto, Ontario-- - Cardiol Therapeutics Inc.   , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced it has achieved the target patient enrollment of 100 patients in \"ARCHER\", its Phase II randomized, double-blind, placebo-controlled trial evaluating the impact of CardiolRx on myocardial recovery in patients with acute myocarditis.Acute myocarditis is an inflammatory condition of the heart muscle  characterized by chest pain, shortness of breath at rest or during activity, fatigue, rapid or irregular heartbeat , and light-headedness or the feeling one might faint. The disease is an important cause of acute and fulminant heart fa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Oc6dugPpSzPTa3FXxNKVlg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/40812b069e3cc4e41dbb262aa2ea973d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Oc6dugPpSzPTa3FXxNKVlg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/40812b069e3cc4e41dbb262aa2ea973d"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cardiol-therapeutics-achieves-target-patient-112700364.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-achieves-target-patient-112700364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4588","BK4007","03160","CRDL","LENZ","BK4139","BK4099","TM","BK4555"],"gpt_icon":0},{"id":"2466439375","title":"Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2466439375","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466439375?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:27","pubTimestamp":1725967620,"startTime":"0","endTime":"0","summary":"Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024. \"Having recently reported the positive primary endpoint data from the MAvERIC-Pilot study demonstrating that oral administration of our small molecule CardiolRx led to marked reductions in pericarditis pain and inflammation at 8 weeks, we are delighted that the data has been accepted for oral presentation in such a prestigious session of the American Heart Association Scientific Sessions 2024, the premier global event for advancements in cardiovascular science and medicine,\" said David Elsley, Cardiol Therapeutics' President and Chief Executive Officer. \"We extend our thanks and gratitude to the patients and our clinical research collaborators whose participation in this important study have served to support our objective of developing a more accessible and non-immunosuppressive therapeutic option for thousands of patient","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CR8YBctZr0n_luGUjBhY8Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/4db45832b8e3a404ec7773324539921f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CR8YBctZr0n_luGUjBhY8Q--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/4db45832b8e3a404ec7773324539921f"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cardiol-therapeutics-announces-completion-maveric-112700136.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-announces-completion-maveric-112700136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4107","CRDL","BK4117","AFG","BK4007","BK4139"],"gpt_icon":0},{"id":"2461317913","title":"Cardiol Therapeutics: First-Mover In CBD-Based Treatment For Heart Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2461317913","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461317913?lang=en_us&edition=fundamental","pubTime":"2024-08-22 20:58","pubTimestamp":1724331486,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics is focused on anti-inflammatory therapies for heart disease, with the lead drug CardiolRx undergoing clinical trials for Pericarditis and Myocarditis.The company's pipeline includ","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/495663426/image_495663426.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/495663426/image_495663426.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4716416-cardiol-therapeutics-first-mover-in-cbd-based-treatment-for-heart-disease","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4534","LU2125154778.USD","BK4559","BK4550","LU0225771236.USD","LU1074936037.SGD","BK4568","LU1032466523.USD","SG9999003800.SGD","CRDL","LU1829250122.USD","LU1093756325.SGD","ACB","LU0882574055.USD","LENZ","BK4532","LU1430594728.SGD","LU2133065610.SGD","IE00B19Z3B42.SGD","IE00BJJMRZ35.SGD","LU0306807586.USD","LU1066053197.SGD","BK4113","AZN","LU0306806265.USD","LU0237698245.USD","LU0109394709.USD","BAYZF","CBD","IE00BSNM7G36.USD","LU2242646821.SGD","SG9999011175.SGD","LU1571399168.USD","IE00B19Z3581.USD","BK4007","LU1883839398.USD","IE0002141913.USD","LU0170899867.USD","LU1670711040.USD","IE00B2B36J28.USD","BK4533","IE00BFTCPJ56.SGD","LU0456855351.SGD","SG9999002232.USD","LU1023059063.AUD","SG9999002224.SGD","LU1718418525.SGD","BMY","IE0009355771.USD"],"gpt_icon":1},{"id":"2461883147","title":"1 Cannabis ETF for Penny Stock Traders to Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2461883147","media":"Barchart","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461883147?lang=en_us&edition=fundamental","pubTime":"2024-08-21 04:19","pubTimestamp":1724185152,"startTime":"0","endTime":"0","summary":"The AdvisorShares Pure Cannabis ETF  is that relatively rare exchange-traded fund  that's gaining attention from penny stock traders, with its price hovering under $5 per share.This ETF provides a gateway into the cannabis market, which has been buzzing with activity lately. The DEA's pending decision to potentially reschedule marijuana to a less harmful category has given cannabis stocks a boost, particularly as more states move to expand adult use. YOLO, for instance, has racked up an 11.9% gain this year.Earlier this year brought the start of limited adult use in Germany, a major European market. Adding to the excitement here in the U.S., Vice President Kamala Harris has become a strong advocate for cannabis reform. As the presidential nominee, her support for changes in federal cannabis laws could be a game-changer for companies with a foothold in the domestic industry.The AdvisorShares Pure Cannabis ETF , launched on April 17, 2019, is an innovative exchange-traded fund that provi","market":"us","thumbnail":"https://media.barchart.com/contributors-admin/common-images/images/Food%2C%20Bev%20%26%20Cannabis/Inspecting%20a%20flower%20by%20HQuality%20via%20Shutterstock.jpg","type":0,"news_type":0,"thumbnails":["https://media.barchart.com/contributors-admin/common-images/images/Food%2C%20Bev%20%26%20Cannabis/Inspecting%20a%20flower%20by%20HQuality%20via%20Shutterstock.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.barchart.com/story/news/28126200/1-cannabis-etf-for-penny-stock-traders-to-consider","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"barchart_highlight","symbols":["BK4557","CRDL","MSOS","YOLO","CURLF","FDN","MORE","BK4588","BK4550","VRNOF","GTBIF","VFF","NAV","SNDL","BK4585","CRLBF","BK4547","HITI","BK4189","TCNNF","BK4007"],"gpt_icon":0},{"id":"2459963373","title":"Cardiol Therapeutics Inc.: Financial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2459963373","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459963373?lang=en_us&edition=fundamental","pubTime":"2024-08-13 05:27","pubTimestamp":1723498062,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics Inc. reported a decrease in total assets from CAD 36.7 million as of D...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-inc-financial-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-inc-financial-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRDL","BK4007"],"gpt_icon":0},{"id":"2458552089","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2458552089","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458552089?lang=en_us&edition=fundamental","pubTime":"2024-08-09 18:00","pubTimestamp":1723197600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.American Axle & Mnfg                             2Q       .11    8:00 AM. Soho House & Co                                 2Q      (.11)   7:30 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVRG","XOS","ACHV","JSPR","AXL","BLDP","ACRV","PAVM","AIRS","TPST","EC","LIF","VTYX","FLUT","RBOT","EARN","CGC","CLRB","GETY","GNLX","ABOS","ICAD","IBTA","SATS","AKRO","NKLA","DERM","CCLD","FNV","BTDR","CCAP","EQ","HUMA","TSHA","CRDL","SLRN","CALT","CLSD","ACLX","BLTE","DARE","CTSO","COCP","FTRE","IRON","YMAB","ATAI","CMMB","BWEN","HBM"],"gpt_icon":1},{"id":"2450227534","title":"We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2450227534","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2450227534?lang=en_us&edition=fundamental","pubTime":"2024-07-12 22:15","pubTimestamp":1720793742,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, Cardiol Therapeutics  shareholders have done very well over the last year, with the share price soaring by 177%. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.Given its strong share price performance, we think it's worthwhile for Cardiol Therapeutics shareholders to consider whether its cash burn is concerning. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth . Let's start with an examination of the business' cash, relative to its cash burn.Does Cardiol Therapeutics Have A Long Cash Runway?Since it has a market capitalisation of CA$188m, Cardiol Therapeutics' CA$22m in cash burn equates to about 12% of its market value. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-keeping-eye-cardiol-therapeutics-141542676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRDL","TSE"],"gpt_icon":0},{"id":"2449217781","title":"Cardiol Therapeutics Inc Files for Mixed Shelf of up to $150 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2449217781","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2449217781?lang=en_us&edition=fundamental","pubTime":"2024-07-06 05:19","pubTimestamp":1720214368,"startTime":"0","endTime":"0","summary":"Cardiol Therapeutics Inc Files for Mixed Shelf of up to $150 Mln - SEC Filing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240705:nFWN3IX0O4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRDL"],"gpt_icon":0},{"id":"2446687035","title":"Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2446687035","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446687035?lang=en_us&edition=fundamental","pubTime":"2024-06-28 00:29","pubTimestamp":1719505740,"startTime":"0","endTime":"0","summary":"Toronto, Ontario-- - Cardiol Therapeutics Inc.   , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders  held virtually via live audio webcast, on June 26, 2024. Shareholders voted in favour of all management resolutions proposed in the Company's management information circular dated May 13, 2024.Resolutions proposed and approved at the Meeting were:. The election of the following directors for the ensuing year: David Elsley, Peter Pekos, Dr. Guillermo Torre-Amione, Colin Stott, Michael Willner, Jennifer Chao, Chris Waddick, Teri Loxam.The appointment of BDO Canada LLP as auditors of the Company until the next annual meeting and the authorization of the directors of the Company to fix the remuneration to be paid to the auditors.The approval of the unallocated awards under the Company's O","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VLPxfbalHWI97hmN67wIIA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/442629f36f7e74ebcaefc3ae413bdb00","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VLPxfbalHWI97hmN67wIIA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/442629f36f7e74ebcaefc3ae413bdb00"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cardiol-therapeutics-reports-results-2024-162900549.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardiol-therapeutics-reports-results-2024-162900549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","BK4007","CRDL"],"gpt_icon":0},{"id":"2446361742","title":"ROTH MKM Initiates Coverage on Cardiol Therapeutics With Buy Rating, $10 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2446361742","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2446361742?lang=en_us&edition=fundamental","pubTime":"2024-06-26 19:42","pubTimestamp":1719402128,"startTime":"0","endTime":"0","summary":"ROTH MKM Initiates Coverage on Cardiol Therapeutics With Buy Rating, $10 Price Target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","CRDL","ROTH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cardiolrx.com","stockEarnings":[{"period":"1week","weight":-0.1505},{"period":"1month","weight":-0.1551},{"period":"3month","weight":-0.202},{"period":"6month","weight":-0.3277},{"period":"1year","weight":0.9427},{"period":"ytd","weight":0.8738}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.27595},{"month":2,"riseRate":0.333333,"avgChangeRate":0.116574},{"month":3,"riseRate":0,"avgChangeRate":-0.097301},{"month":4,"riseRate":0.666667,"avgChangeRate":0.092473},{"month":5,"riseRate":0.666667,"avgChangeRate":0.123182},{"month":6,"riseRate":0.333333,"avgChangeRate":0.025449},{"month":7,"riseRate":0.666667,"avgChangeRate":0.094263},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.078283},{"month":9,"riseRate":0.5,"avgChangeRate":-0.034119},{"month":10,"riseRate":0,"avgChangeRate":-0.177472},{"month":11,"riseRate":0.25,"avgChangeRate":-0.151241},{"month":12,"riseRate":0,"avgChangeRate":-0.055088}],"exchange":"NASDAQ","name":"Cardiol Therapeutics Inc","nameEN":"Cardiol Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cardiol Therapeutics Inc(CRDL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cardiol Therapeutics Inc(CRDL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cardiol Therapeutics Inc,CRDL,Cardiol Therapeutics Inc股票,Cardiol Therapeutics Inc股票老虎,Cardiol Therapeutics Inc股票老虎国际,Cardiol Therapeutics Inc行情,Cardiol Therapeutics Inc股票行情,Cardiol Therapeutics Inc股价,Cardiol Therapeutics Inc股市,Cardiol Therapeutics Inc股票价格,Cardiol Therapeutics Inc股票交易,Cardiol Therapeutics Inc股票购买,Cardiol Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cardiol Therapeutics Inc(CRDL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cardiol Therapeutics Inc(CRDL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction